by leveraging our immunology expertise, hcw is developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell clearance.
Company profile
Ticker
HCWB
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
825024477
HCWB stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Apr 24
8-K
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End
1 Apr 24
D
$2.50 mm in equity, sold $2.50 mm, 6 investors
27 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Termination of a Material Definitive Agreement
12 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
HCW Biologics Reports Third Quarter 2023 Financial Results
14 Nov 23
8-K
Other Events
31 Aug 23
8-K
Other Events
24 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.22 mm | 11.22 mm | 11.22 mm | 11.22 mm | 11.22 mm | 11.22 mm |
Cash burn (monthly) | (no burn) | 1.25 mm | 1.69 mm | 1.72 mm | 1.86 mm | 1.87 mm |
Cash used (since last report) | n/a | 8.32 mm | 11.26 mm | 11.43 mm | 12.40 mm | 12.42 mm |
Cash remaining | n/a | 2.90 mm | -41.02 k | -209.96 k | -1.18 mm | -1.20 mm |
Runway (months of cash) | n/a | 2.3 | -0.0 | -0.1 | -0.6 | -0.6 |
Institutional ownership, Q2 2023
2.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 2.17 bn |
Total shares | 1.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HighTower Advisors | 354.87 k | $770.00 mm |
Vanguard | 187.09 k | $405.99 mm |
Cresset Asset Management | 131.99 k | $286.42 mm |
Geode Capital Management | 131.03 k | $284.34 mm |
Bridgeway Capital Management | 82.60 k | $179.24 mm |
BLK Blackrock | 49.69 k | $107.82 mm |
Two Sigma Investments | 26.54 k | $57.59 mm |
STT State Street | 21.45 k | $46.54 mm |
NTRS Northern Trust | 10.21 k | $22.15 mm |
Tower Research Capital | 3.69 k | $8.01 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Scott T Garrett | Common Stock | Grant | Acquire A | Yes | No | 1.4 | 142,858 | 200.00 k | 267,858 |
20 Feb 24 | Lee Flowers | Common Stock | Grant | Acquire A | No | No | 1.4 | 71,429 | 100.00 k | 190,238 |
20 Feb 24 | Rebecca Byam | Common Stock | Grant | Acquire A | No | No | 1.4 | 760,714 | 1.06 mm | 1,381,909 |
20 Feb 24 | Hing C Wong | Common Stock | Grant | Acquire A | No | No | 1.4 | 739,288 | 1.04 mm | 16,054,156 |
20 Feb 24 | Rick S. Greene | Common Stock | Grant | Acquire A | No | No | 1.4 | 35,714 | 50.00 k | 44,125 |